-1,11 %
+2,41 %
-17,88 %
-75,52 %
-74,54 %
-80,03 %
-82,77 %
-88,10 %
-85,37 %
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Læs mereMarkedsværdi
111,32 mio. EUR
Aktieomsætning
248,22 t EUR
P/E (adj.) (26e)
-4,73
EV/EBIT (adj.) (26e)
-5,45
P/B (26e)
84,77
EV/S (26e)
25.902,39
Udbytteafkast, % (26e)
-
